NEW YORK (GenomeWeb) – Fred Hutchinson Cancer Research Center spinout Adaptive Biotechnologies has acquired immune sequencing company Sequenta, the companies said today.

Adaptive Biotechnologies CEO Chad Robins will remain as CEO of the combined company. Tom Willis, Sequenta co-founder and CEO, and Malek Faham, co-founder and chief scientific officer of Sequenta, will join the senior leadership team and report to Robins. Willis and John Stuelpnagel, Sequenta's chairman, will join the board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.